Utilizing a recently identified gene coexpression network defining SCLC neuroendocrine and mesenchymal states [18, 19], we have identified that sensitivity to LSD1 inhibitors in SCLC is confined primarily to cell lines that express neuroendocrine transcriptional programs. This evidence concerns the gene KDM1A and small cell lung carcinoma.